Abstract 457P
Background
Vitamin D deficiency is associated with various kinds of cancer. Moreover, vitamin D level possibly has an inverse relationship with cancer mortality. The data on vitamin D status among Thai cancer patients and its association with cancer survival are scarce. Objectives: The primary outcome was to determine the prevalence of vitamin D deficiency among unselected Thai cancer patients. The secondary outcomes were to explore the effect of cancer treatment upon vitamin D status, the independent predictive factor(s) of vitamin D deficiency among cancer patients and its potential independent factor of cancer survival.
Methods
There were 106 consecutive cancer patients participated in this prospective descriptive study conducted at Division of Medical Oncology. Vitamin D (25(OH) D) levels were collected before and after cancer treatment. Demographic data, vitamin D status, and treatment outcomes were collected and analysed.
Results
There were 106 consecutive cancer patients participated in this study. Determination of vitamin D status after cancer treatment were obtained in 76 patients. The investigators found that almost all of the cancer patients had vitamin D deficiency (102 of 106, 96.2%). Determination of vitamin D status after cancer treatment were obtained in 76 patients. The investigators did not demonstrate the significant change of vitamin D level (mean change = -1.46 (95% C.I., -3.33-0.41), p = 0.124) when the blood samples were collected before and after cancer treatment. Therefore, cancer treatment was unlikely to affect the vitamin D status. There was a trend towards inverse relationship between the BMI and vitamin D level. At the median follow-up time of 254.5 days (IQR 220-297), the investigators revealed that low BSA (BSA < 1.5 m2), PS 2 at presentation was the independent predictive factors of survival, according to the multi-variate analysis.
Conclusions
Nearly all Thai cancer patients have vitamin D deficiency. Cancer treatment does not affect the vitamin D status. Low serum vitamin D level does not affect survival outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Chavapon Ngokngarm/Vajira hospital, Thailand.
Funding
Medical Research Fund of Faculty Medicine Vajira Hospital, Navamindradhiraj University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract